Erythropoietin Drugs Market by Product Type (Epoetin-Alfa, Epoetin-Beta, and Darbepoetin-Alfa, Others) and Application (Hematology, Kidney Disorder, Cancer, Others): Global Opportunity Analysis and Industry Forecast, 2021–2028
- ALL4621673
- 165 Pages
- May 2021
- Medical Devices
Erythropoietin is a glycoprotein hormone synthesized in the bone marrow that controls and regulates mechanism of erythropoiesis (production of red blood cells). These erythropoietin (EPO) drugs are used for treatment of chemotherapy-induced anemia. Improved recombinant DNA technology has led to development of synthetic forms of erythropoietin such as epoetin-alfa, epoetin-beta, darbepoetin-alfa, epoetin-omega, and epoetin-delta.
Rise in number of patients suffering from anemic conditions induced due to cancer, HIV and ESRD treatment, favorable reimbursements, and increase in commercialization of EPO biosimilars are the major factors for the market growth. However, side effects such as arterial hypertension, iron deficiency, influenza-like syndrome, and longer treatment period (4-6 weeks) hampers growth of erythropoietin drugs market. Availability of numerous biosimilars has rendered low-cost options for patients, therefore, increased adoption rates for EPO drugs particularly in developing regions, which boosts the market growth. Furthermore, commercialization patterns for erythropoietin biosimilars, readily available reimbursements, favorable government regulations, and awareness regarding benefits of EPO therapeutics contribute toward growth of erythropoietin drugs market.
The global erythropoietin drugs market is segmented into product type, application, and region. On the basis of product type, the market is categorized into epoetin-alfa, epoetin-beta, darbepoetin alfa. By application, it is classified into anemia, kidney disorders, and others. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
KEY BENEFITS FOR STAKEHOLDERS
• The study provides an in-depth analysis of the global erythropoietin drugs market along with the current trends and future estimations to elucidate the imminent investment pockets.
• A comprehensive analysis of the factors that drive and restrict the market growth is provided in the report.
• Comprehensive quantitative analysis of the industry from 2020 to 2028 is provided to enable the stakeholders to capitalize on the prevailing market opportunities.
• Extensive analysis of the key segments of the industry helps to understand the application and products of erythropoietin used across the globe.
• Key market players and their strategies have been analyzed to understand the competitive outlook of the market.
KEY MARKET SEGMENTS
By Type
• Epoetin-alfa
• Epoetin-beta
• Darbepoetin alfa
By Application
• Anemia
• Kidney Disorders
Others
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o France
o UK
o Italy
o Spain
o Rest of Europe
• Asia-Pacific
o Japan
o China
o India
o Australia
o South Korea
o Rest of Asia-Pacific
• LAMEA
o Brazil
o Saudi Arabia
o South Africa
o Rest of LAMEA
LIST OF KEY PLAYERS PROFILED IN THE REPORT
• Amgen Inc.
• Biocon,
• Celltrion, Inc.
• Intas Pharmaceuticals
• Johnson & Johnson
• Hospira Inc.
• Intas Pharmaceuticals
• LG Life Sciences Ltd.
• Roche
• Ranbaxy Laboratories Ltd.
• Teva Pharmaceutical Industries Ltd.
1.1.Report description
1.2.Key benefits
1.3.Key market segments
1.4.Research methodology
1.4.1.Primary research
1.4.2.Secondary Research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Clinical trials for EPO drug
3.3.Market share analysis, 2020
3.4.Market dynamics
3.4.1.Drivers
3.4.1.1.Increasing number cases: including cancer,HIV, kidney disease and anaemia
3.4.1.2.Growing trends of commercialization for erythropoietin biosimilars
3.4.1.3.Increasing level of awareness about the benefits of EPO therapeutics
3.4.2.Restraints
3.4.2.1.Unaffordability of therapeutics
3.4.2.2.Longer duration of treatments
3.4.2.3.Adverse amount of side effects
3.4.3.Opportunities
3.4.3.1.Commercialization of Darbepoetin alfa biosimilar
3.4.3.2.Achieving Economies of scale across developed region with biosimilar version of EPO
3.5.Impact of Covid-19 on Erythropoietin Drug Market
CHAPTER 4:GLOBAL ERYTHROPOIETIN MARKET BY PRODUCTS
4.1.Epoetin-alfa
4.1.1.Key market trends and opportunities
4.1.2.Market size and forecast
4.1.3.Market analysis, by country
4.2.Epoetin-beta
4.2.1.Key market trends and opportunities
4.2.2.Market size and forecast
4.2.3.Market analysis, by country
4.3.Darbepoetin-alfa
4.3.1.Key market trends and opportunities
4.3.2.Market size and forecast
4.3.3.Market analysis, by country
4.4.Other
4.4.1.Key market trends and opportunities
4.4.2.Market size and forecast
4.4.3.Market analysis, by country
CHAPTER 5:GLOBAL ERYTHROPOIETIN MARKET BY APPLICATIONS
5.1.Hematology
5.1.1.Market size and forecast
5.1.2.Market analysis, by country
5.2.Kidney Disorders (ESRD and Dialysis)
5.2.1.Market size and forecast
5.2.2.Market analysis, by country
5.3.Cancer
5.3.1.Market size and forecast
5.3.2.Market analysis, by country
5.4.Others
5.4.1.Market size and forecast
5.4.2.Market analysis, by country
CHAPTER 6:GLOBAL ERYTHROPOIETIN MARKET BY GEOGRAPHY
6.1.North America
6.1.1.Key market trends & opportunities
6.1.2.Market size and forecast
6.2.Europe
6.2.1.Key market trends & opportunities
6.2.2.Market size and forecast
6.3.Asia-Pacific
6.3.1.Key market trends & opportunities
6.3.2.Market size and forecast
6.4.LAMEA
6.4.1.Key market trends & opportunities
6.4.2.Market size and forecast
CHAPTER 7:COMPANY PROFILES
7.1.AMGEN INC.
7.1.1.Company overview
7.1.2.Amgen Inc. snapshot
7.1.3.Operating Business Segment
7.1.4.Financial performance
7.2.JOHNSON AND JOHNSON
7.2.1.Company overview
7.2.2.Johnson & Johnson snapshot
7.2.3.Operating Business Segment overview
7.2.4.Financial performance
7.3.ROCHE DIAGNOSTICS
7.3.1.Company overview
7.3.2.Roche Diagnostics snapshot
7.3.3.Operating Business Segment Overview
7.3.4.Financial performance
7.4.HOSPIRA INC.
7.4.1.Company overview
7.4.2.Hospira Inc. snapshot
7.4.3.Operating business segment
7.4.4.Financial performance
7.4.5.Key Strategies move & development
7.5.LG LIFE SCIENCES LTD.
7.5.1.Company overview
7.5.2.LG Life Sciences Ltd. snapshot
7.5.3.Operating Business segment overview
7.5.4.Financial performance
7.6.BIOCON
7.6.1.Company overview
7.6.2.Biocon snapshot
7.6.3.Operating Business Segment Overview
7.6.4.Financial performance
7.6.5.Key Strategies move and development
7.7.INTAS PHARMACEUTICALS
7.7.1.Company overview
7.7.2.Intas Pharmaceuticals snapshot
7.7.3.Operating Business Segment Overview
7.7.4.Financial performance
7.8.TEVA PHARMACEUTICAL INDUSTRIES LTD.
7.8.1.Company overview
7.8.2.Teva Pharmaceutical Industries Ltd. snapshot
7.8.3.Operating business segment overview
7.8.4.Financial performance
7.9.RANBAXY LABORATORIES LTD.
7.9.1.Company overview
7.9.2.Ranbaxy Laboratories Ltd. snapshot
7.9.3.Operating business segment overview
7.9.4.Financial performance
7.10.CELLTRION, INC
7.10.1.Company overview
7.10.2.Celltrion, Inc. snapshot
7.10.3.Financial performance
TABLE 01.CLINICAL TRIALS OF ERYTHROPOEITIN FOR NEURAL DISEASES AND WOUND HEALING
TABLE 02.GLOBAL ERYTHROPOIETIN DRUG MARKET BY PRODUCT TYPES, 2020-2028($MILLION)
TABLE 03.GLOBAL ERYTHROPOIETIN ALFA DRUGS MARKET BY GEOGRAPHY, 2020-2028($MILLION)
TABLE 04.GLOBAL ERYTHROPOIETIN BETA DRUGS MARKET BY GEOGRAPHY, 2020-2028($MILLION)
TABLE 05.GLOBAL DARBEPOETIN ALFA DRUGS MARKET BY GEOGRAPHY, 2020-2028($MILLION)
TABLE 06.GLOBAL OTHER DRUGS MARKET BY GEOGRAPHY, 2020-2028($MILLION)
TABLE 07.GLOBAL ERYTHROPOIETIN MARKET BY APPLICATIONS, 2020-2028($MILLION)
TABLE 08.GLOBAL HEMATOLOGY APPLICATION MARKET BY GEOGRAPHY, 2020-2028, $MILLION
TABLE 09.GLOBAL ESRD AND DIALYSIS INDUCED ANEMIA ERYTHROPOIETIN DRUGS APPLICATION MARKET BY GEOGRAPHY, 2020-2028, $MILLION
TABLE 10.GLOBAL CANCER APPLICATION MARKET BY GEOGRAPHY, 2020-2028, $MILLION
TABLE 11.GLOBAL OTHERS APPLICATION MARKET BY GEOGRAPHY, 2020-2028, $MILLION
TABLE 12.GLOBAL ERYTHROPOETIN MARKET BY GEOGRAPHY, 2020 – 2020 ($MILLION)
TABLE 13.NORTH AMERICA ERYTHROPOETIN MARKET BY PRODUCT TYPES, 2020 – 2020 ($MILLION)
TABLE 15.EUROPE ERYTHROPOETIN MARKET BY PRODUCT TYPES, 2020 – 2020 ($MILLION)
TABLE 17.ASIA-PACIFIC ERYTHROPOETIN MARKET BY PRODUCT TYPES, 2020 – 2020 ($MILLION)
TABLE 18.LAMEA ERYTHROPOETIN MARKET BY PRODUCT TYPES, 2020 – 2020 ($MILLION)
TABLE 19.AMGEN INC. SNAPSHOT
TABLE 20.AMGEN INC. OPERATING BUSINESS SEGMENT
TABLE 21.JOHNSON & JOHNSON SNAPSHOT
TABLE 22.JOHNSON AND JOHNSON OPERATING SEGEMENTS
TABLE 23.ROCHE DIAGNOSTICS SNAPSHOT
TABLE 24.ROCHE DIAGNOSTICS OPERATING SEGEMENTS
TABLE 25.HOSPIRA INC. SNAPSHOT
TABLE 26.HOSPIRA INC. OPERATING SEGEMENTS
TABLE 27.LG LIFE SCIENCES LTD. DIAGNOSTICS SNAPSHOT
TABLE 28.LG LIFE SCIENCES LTD. DIAGNOSTICS OPERATING SEGEMENTS
TABLE 29.BIOCON SNAPSHOT
TABLE 30.BIOCON OPERATING SEGEMENTS
TABLE 31.INTAS PHARMACEUTICALS SNAPSHOT
TABLE 32.INTAS PHARMACEUTICALS OPERATING SEGEMENTS
TABLE 33.TEVA PHARMACEUTICAL INDUSTRIES LTD. SNAPSHOT
TABLE 34.TEVA PHARMACEUTICAL INDUSTRIES LTD. OPERATING SEGEMENTS
TABLE 35.RANBAXY LABORATORIES LTD. SNAPSHOT
TABLE 36.CELLTRION, INC. SNAPSHOT
Similar Reports
Medical implants are permanent devices such as pacemakers or temporary devices such as fracture plates which are removed once their function is completed. These implants are made up of bone, tissue, skin, ceramics, metals, plastics, and other natural materials...
- Publish Date: August 21, 2016
- $5370
Ostomy is a surgery wherein an artificial opening, known as stoma, is created from the colon in the human body to eliminate body wastes such as urine, mucus, and stools, which are collected in artificial bags called ostomy drainage bags. These plastic/rub...
- Publish Date: December 1, 2016
- $5370
Laparoscopy is a minimally invasive procedure used to examine organs inside the abdomen or pelvic cavities by inserting a laparoscope through a small incision in the abdomen. A laparoscope comprises a long, thin tube with high-intensity light, and high-re...
- Publish Date: April 24, 2017
- $5370
